

*Email Subject Line: Update on Availability of Trulicity® (dulaglutide) 1.5 mg in Australia*

[View this email in your browser](#)



## **IMPORTANT INFORMATION FOR HEALTHCARE PROFESSIONALS**

### **Update on availability of Trulicity® (dulaglutide) 1.5 mg in Australia**

1 September 2022

Dear Healthcare Professional,

#### **TRULICITY® (dulaglutide) 1.5 mg is current of limited availability**

Eli Lilly Australia (Lilly) has been and is continuing to experience an unanticipated increase in demand of our Type 2 Diabetes (T2D) medication, Trulicity (dulaglutide).<sup>1</sup> This increase is driven by the supply issues of Ozempic® (semaglutide),<sup>2</sup> another pharmaceutical company's T2D medication.

On 4 August 2022, the expected period of semaglutide shortage in Australia was updated on the TGA medicine shortage database to 31 December 2022. As a result, Lilly has extended the Limited Availability status for Trulicity on the TGA medicine shortage database to 31 December 2022.<sup>2</sup>

With limited availability of stock, Lilly anticipates delays, interruptions and/or shortages in stock available through wholesalers and at pharmacies during this time.

Lilly is committed to maintaining supply of Trulicity 1.5mg in Australia. Our priority in the current circumstances is to ensure that Trulicity remains available for patients with T2D.

Lilly is in frequent contact with wholesalers, and together we are closely monitoring stock levels. We are releasing stock to wholesalers as equitably as possible. We anticipate that patients could experience delays of several weeks in having their prescriptions filled, depending on location and wholesaler. Lilly does not have visibility of stock on hand at pharmacies.

During this period, Lilly recommends that pharmacists consider the following to help manage access to Trulicity for patients with T2D:

- Limit dispensing to one (1) month of medication at a time.
- Advise patients they could experience delays of several weeks in having their prescriptions filled.
- Remind patients to contact the pharmacy as early as possible to have their prescription filled, so that timely supply can be organised. Encourage patients to leave their prescription with their regular pharmacy.
- Advise patients who have missed a dose to consult with their healthcare professional and refer to the [Trulicity Consumer Medicine Information](#) for additional guidance.
- Order stock of Trulicity through your usual wholesaler/s.  
Please note that Community Service Obligation (CSO) Distributors have been directed to responsibly supply Trulicity and may restrict supply on an appropriate and equitable basis in accordance with Written Directions from the Department of Health, effective 26 August 2022 until 31 January 2023.

We recognise the inconvenience these disruptions may cause and will provide relevant updates via [lilly.com.au](http://lilly.com.au). For any further information or support, please contact our Lilly Australia Medical Information team on 1800 454 559/ 1800 4 LILLY.

If you have further questions about Trulicity, please contact the Lilly Medical Information team on 1800 454 559 /1800 4 LILLY (operating hours Monday to Friday, 9am – 5pm AEST).

Yours Sincerely,

**Benjamin Basil,**

President & General Manager  
Australia, New Zealand & North Asia-Pacific

References: 1.Trulicity Approved Product Information, July 2020. 2. Australian Department of Health, Therapeutic Goods Administration, available at <http://apps.tga.gov.au/Prod/msi/search?shortagetype=All>, last accessed 30 August 2022

OZEMPIC® is a registered trademark of Novo Nordisk AB  
TRULICITY® is a registered trademark of Eli Lilly and Company

PBS Information: Authority Required (STREAMLINED). Type 2 Diabetes. Criteria Apply.  
Refer to PBS Schedule for full Authority Required Information.

Please refer to the full product information before prescribing. Full product Information can be accessed at [www.lilly.com.au/en/products](http://www.lilly.com.au/en/products) or on request by calling 1800 454 559.

**INDICATIONS** – TRULICITY is indicated for adult patients with Type 2 diabetes as 1) an adjunct to diet and exercise to improve glycaemic control; and 2) as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events in those with either established cardiovascular disease or multiple risk factors for cardiovascular disease. **CONTRAINDICATIONS** – Hypersensitivity to dulaglutide or any of the excipients. **PRECAUTIONS** – should not be used in patients with Type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis; severe gastrointestinal disease – not recommended; acute pancreatitis – discontinue treatment if suspected; hypoglycaemia – combining treatment with sulfonylurea or insulin may increase risk; congestive heart failure – limited therapeutic experience. Use in Pregnancy Category B3. **ADVERSE EFFECTS Clinical Trials Experience** – Very Common (≥10%) gastrointestinal disorders (nausea, vomiting and diarrhoea), hypoglycaemia (in combination with insulin non-/secretagogues and/or insulin); Common (≥1 and <10%) abdominal pain, decreased appetite, dyspepsia, fatigue, hypoglycaemia (as monotherapy), immunogenicity, atrial fibrillation. **DOSAGE AND ADMINISTRATION** – Dosage: Adults (≥ 18 years): 1.5 mg once weekly, at any time of day, independently of meals. Elderly Patients (≥65 years): dose adjustment not required. Children and adolescents (<18 years): safety and effectiveness have not been established. Renal Impairment: no dose adjustment is required in mild, moderate or severe renal impairment; not recommended in end-stage renal disease. Hepatic Impairment: no dose adjustment required. Administration: subcutaneous injection in the abdomen, thigh or upper arm. Should not be administered intravenously or intramuscularly. Single-use in one patient only. Discard the pen once the injection is completed.

Please review full PI before prescribing. Full PI is available on request from Eli Lilly. Eli Lilly Australia Pty Ltd, 112 Wharf Road, West Ryde NSW 2114. Phone 1800 454 559. Based on PI approved 14 July 2020.

TRULICITY® is a registered trademark of Eli Lilly and Company. PP-DG-AU-0908. August 2022

The Lilly logo is written in a red, cursive script font.